Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorProwle, John Ren
dc.contributor.authorCalzavacca, Paoloen
dc.contributor.authorLicari, Elisaen
dc.contributor.authorLigabo, Emmanuela Ven
dc.contributor.authorEcheverri, Jorge Een
dc.contributor.authorHaase, Michaelen
dc.contributor.authorHaase-Fielitz, Anjaen
dc.contributor.authorBagshaw, Sean Men
dc.contributor.authorDevarajan, Prasaden
dc.contributor.authorBellomo, Rinaldoen
dc.identifier.citationNephrology; 17(3): 215-24en
dc.description.abstractTo test whether short-term perioperative administration of oral atorvastatin could reduce incidence of postoperative acute kidney injury (AKI) in cardiac surgical patients.We conducted a double-blind, randomized controlled trial in 100 cardiac surgical patients at increased risk of postoperative AKI. Patients were randomized to atorvastatin (40 mg once daily for 4 days starting preoperatively) or identical placebo capsule. Primary outcome was to detect a smaller absolute rise in postoperative creatinine with statin therapy. Secondary outcomes included AKI defined by the creatinine criteria of RIFLE consensus classification (RIFLE R, I or F), change in urinary neutrophil gelatinase-associated lipocalin (NGAL) concentration, requirement for renal replacement therapy, length of stay in intensive care, length of stay in hospital and hospital mortality.Study groups were well matched. For each patient maximal increase in creatinine during the 5 days after surgery was assessed; median maximal increase was 28 µmol/L in the atorvastatin group and 29.5 µmol/L in the placebo group (P = 0.62). RIFLE R or greater occurred in 26% of patients with atorvastatin and 32% with placebo (P = 0.65). Postoperatively urine NGAL changes were similar (median NGAL : creatinine ratio at intensive care unit admission: atorvastatin group 1503 ng/mg, placebo group 1101 ng/mg; P = 0.22). Treatment was well tolerated and adverse events were similar between groups.Short-term perioperative atorvastatin use was not associated with a reduced incidence of postoperative AKI or smaller increases in urinary NGAL. ( NCT00910221).en
dc.subject.otherAcute Kidney Injury.prevention & controlen
dc.subject.otherAcute-Phase Proteins.urineen
dc.subject.otherCardiac Surgical Procedures.adverse effectsen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherHeptanoic Acids.therapeutic useen
dc.subject.otherHydroxymethylglutaryl-CoA Reductase Inhibitors.therapeutic useen
dc.subject.otherMiddle Ageden
dc.subject.otherMultivariate Analysisen
dc.subject.otherPilot Projectsen
dc.subject.otherPostoperative Complications.prevention & controlen
dc.subject.otherProto-Oncogene Proteins.urineen
dc.subject.otherPyrroles.therapeutic useen
dc.titlePilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.en
dc.typeJournal Articleen
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen
dc.type.austinJournal Articleen, Rinaldo
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications- Care- Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.